1. European Glaucoma Society. Terminology and guidelines for glaucoma. 3rd ed. Savona: DOGMA; 2008.
2. Kuwayama Y, Komemushi S. Phase III confirmatory study of 0.0015% DE-085 (tafluprost) ophthalmic solution as compared to 0.005% latanoprost ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. Atarashii Ganka (J Eye). 2008;25:1595–602.
3. Kuwayama Y, Komemushi S, Tafluprost Multi-center Study Group. Intraocular pressure-lowering effect of 0.0015% tafluprost as compared to placebo in patients with normal-tension glaucoma: randomized, double-blind, multicenter, phase III study. Nippon Ganka Gakkai Zasshi. 2010;114:436–43.
4. Kuwayama Y, Nomura A. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety. Adv Ther. 2014;31:461–71.
5. Iwase A, Suzuki Y, Araie M, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 2004;111:1641–8.